For decades, Indian parents relied on a simple remedy whenever a child coughed: a spoonful of cough syrup. But the industry is witnessing a major shift. Across paediatric clinics, pharmacies, and regulatory circles, there is a new seriousness about how cough syrups for children are prescribed, manufactured, and monitored.
As a small and medium drug manufacturing company, we see this not as a setback — but as a turning point for strengthening trust, improving quality standards, and ensuring safer paediatric care nationwide.
A Wake-Up Call That Reshaped the Industry
Recent tragic incidents involving contaminated cough syrups have forced the entire ecosystem — manufacturers, regulators, prescribers, and pharmacists — to re-evaluate the safety of paediatric liquid formulations. Investigations uncovered unacceptable levels of harmful substances, pointing to preventable lapses in quality control.
This led to:
- Stricter regulatory scrutiny
- Mandatory prescriptions for specific paediatric syrups in some states
- Union Health Ministry advisories urging rational prescribing
- Renewed attention to Good Manufacturing Practices (GMP)
For responsible manufacturers like us, these events highlight the need for uncompromising quality systems, validated processes, and transparent supply chains.
Why Doctors Are Changing Their Approach
Paediatricians across India now follow updated guidance that discourages routine use of cough syrups in young children. Most childhood coughs are viral and self-limiting, improving naturally within a week.
Doctors caution against unnecessary syrup use because:
- Cough syrups don’t treat infections; they only suppress symptoms
- Some ingredients can cause drowsiness, vomiting, or breathing issues in infants
- Combining multiple cold medicines risks accidental overdosing
The CDSCO and expert panels now advise avoiding fixed-dose cough combinations in children below four years. As manufacturers, these guidelines push us to adopt clearer labelling, more robust safety data, and precise dosing communication.
Where Cough Syrups Still Have a Role
While unnecessary use is declining, cough syrups remain relevant when:
- A child’s cough disrupts sleep and persists beyond recovery
- Allergies or asthma require targeted formulations
- Wet coughs need expectorants to loosen thick mucus
- Bacterial infections require short-term symptom relief alongside antibiotics
For us, this means designing formulations backed by evidence, ensuring stability and purity, and maintaining dosage accuracy — especially for weight-based paediatric requirements.
Empowering Parents With Safe Alternatives
Parents now play a more active role in home-based supportive care. Doctors encourage:
- Increased fluid intake
- Saline nasal drops
- Steam inhalation
- Honey for children above one year
- Avoiding OTC self-medication
These practices emphasise that pharmaceuticals should support — not replace — natural recovery.
Our Commitment as a Responsible Drug Manufacturer
This changing landscape is an opportunity for India’s MSME pharma sector to lead with integrity. At our manufacturing unit, we commit to:
- 100% compliance with GMP-WHO standards
- Batch-wise testing for impurities and contaminants
- Transparent sourcing of raw materials
- Improved pharmacovigilance practices
- Clear, accurate labelling and paediatric dosing charts
- Continuous training for quality and regulatory teams
In an era where trust matters more than ever, we aim to be a partner to doctors, parents, and regulators in ensuring that every bottle leaving our facility meets the highest safety standards.